NASDAQ:ALKS - Nasdaq - IE00B56GVS15 - Common Stock - Currency: USD
Taking everything into account, ALKS scores 6 out of 10 in our fundamental rating. ALKS was compared to 556 industry peers in the Biotechnology industry. ALKS gets an excellent profitability rating and is at the same time showing great financial health properties. ALKS scores decently on growth, while it is valued quite cheap. This could make an interesting combination. This makes ALKS very considerable for value investing!
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 16.91% | ||
ROE | 23.28% | ||
ROIC | 20.05% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 25.9% | ||
PM (TTM) | 23.25% | ||
GM | 84.42% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | 0 | ||
Altman-Z | 5.91 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 3.33 | ||
Quick Ratio | 2.92 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 9.54 | ||
Fwd PE | 14.21 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 8.93 | ||
EV/EBITDA | 7.15 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
26.13
-0.4 (-1.51%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 9.54 | ||
Fwd PE | 14.21 | ||
P/S | 2.85 | ||
P/FCF | 8.93 | ||
P/OCF | 8.33 | ||
P/B | 2.85 | ||
P/tB | 3.02 | ||
EV/EBITDA | 7.15 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 16.91% | ||
ROE | 23.28% | ||
ROCE | 23.93% | ||
ROIC | 20.05% | ||
ROICexc | 43.56% | ||
ROICexgc | 49.02% | ||
OM | 25.9% | ||
PM (TTM) | 23.25% | ||
GM | 84.42% | ||
FCFM | 31.86% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | 0 | ||
Debt/EBITDA | 0 | ||
Cap/Depr | 122.21% | ||
Cap/Sales | 2.29% | ||
Interest Coverage | 250 | ||
Cash Conversion | 122.99% | ||
Profit Quality | 137.03% | ||
Current Ratio | 3.33 | ||
Quick Ratio | 2.92 | ||
Altman-Z | 5.91 |